

Eric P Krenning

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/407033/publications.pdf>

Version: 2024-02-01

310
papers

25,238
citations

4960

84
h-index

8396

147
g-index

318
all docs

318
docs citations

318
times ranked

15419
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastroenteropancreatic neuroendocrine tumours. <i>Lancet Oncology</i> , The, 2008, 9, 61-72.	10.7	1,474
2	Treatment With the Radiolabeled Somatostatin Analog [¹⁷⁷ Lu-DOTA ⁰ , Tyr ³]Octreotate: Toxicity, Efficacy, and Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 2124-2130.	1.6	1,307
3	The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors. <i>Endocrine Reviews</i> , 1991, 12, 450-482.	20.1	776
4	Radiolabeled Somatostatin Analog [¹⁷⁷ Lu-DOTA ⁰ , Tyr ³]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 2754-2762.	1.6	602
5	The origin of fibroblasts and mechanism of cardiac fibrosis. <i>Journal of Cellular Physiology</i> , 2010, 225, 631-637.	4.1	509
6	[¹⁷⁷ Lu-DOTA ⁰ , Tyr ³]octreotate: comparison with [¹¹¹ In-DTPA ⁰]octreotide in patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1319-1325.	2.1	431
7	Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2010, 17, R53-R73.	3.1	409
8	Long-Term Efficacy, Survival, and Safety of [¹⁷⁷ Lu-DOTA ⁰ , Tyr ³]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4617-4624.	7.0	399
9	Bone Mineral Density in Children and Adolescents: Relation to Puberty, Calcium Intake, and Physical Activity ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 57-62.	3.6	391
10	Phase I study of peptide receptor radionuclide therapy with [¹¹¹ In-DTPA ⁰]octreotide: The rotterdam experience. <i>Seminars in Nuclear Medicine</i> , 2002, 32, 110-122.	4.6	364
11	Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 5-19.	6.4	357
12	Endothelial to Mesenchymal Transition in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 190-209.	2.8	357
13	Plasma Membrane Transport of Thyroid Hormones and Its Role in Thyroid Hormone Metabolism and Bioavailability. <i>Endocrine Reviews</i> , 2001, 22, 451-476.	20.1	340
14	Prednisone and Cyclosporine in the Treatment of Severe Graves' Ophthalmopathy. <i>New England Journal of Medicine</i> , 1989, 321, 1353-1359.	27.0	321
15	Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. <i>Seminars in Nuclear Medicine</i> , 2002, 32, 133-140.	4.6	307
16	Survival and Response After Peptide Receptor Radionuclide Therapy With [⁹⁰ Y-DOTA ⁰ , Tyr ³]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2006, 36, 147-156.	4.6	283
17	Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 9-15.	6.4	266
18	Radiolabelling DOTA-peptides with ⁶⁸ Ga. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 478-485.	6.4	248

#	ARTICLE	IF	CITATIONS
19	Endothelial-to-mesenchymal transition in atherosclerosis. <i>Cardiovascular Research</i> , 2018, 114, 565-577.	3.8	239
20	[¹²³ I]Metaiodobenzylguanidine and [¹¹¹ In]Octreotide Uptake in Benign and Malignant Pheochromocytomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 685-693.	3.6	233
21	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs. <i>Neuroendocrinology</i> , 2009, 90, 220-226.	2.5	232
22	Somatostatin receptor imaging. <i>Seminars in Nuclear Medicine</i> , 2002, 32, 84-91.	4.6	212
23	⁸⁶ Y-DOTA ⁰ -d-Phe ¹ -Tyr ³ -octreotide (SMT487) a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 510-518.	6.4	212
24	Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. <i>Acta Oncologica</i> , 2007, 46, 723-734.	1.8	200
25	Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. <i>Journal of Pediatrics</i> , 2002, 141, 204-210.	1.8	196
26	¹⁷⁷ Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 1752-1763.	10.7	195
27	Optimising conditions for radiolabelling of DOTA-peptides with ⁹⁰ Y, ¹¹¹ In and ¹⁷⁷ Lu at high specific activities. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 917-920.	6.4	194
28	Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1421-1429.	2.1	193
29	Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³]octreotate. <i>Journal of Clinical Oncology</i> , 2004, 22, 2724-2729.	1.6	191
30	Parallel <i>in Vivo</i> and <i>in Vitro</i> Detection of Functional Somatostatin Receptors in Human Endocrine Pancreatic Tumors: Consequences with Regard to Diagnosis, Localization, and Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 71, 566-574.	3.6	190
31	Endothelial-to-mesenchymal transition contributes to fibro-proliferative vascular disease and is modulated by fluid shear stress. <i>Cardiovascular Research</i> , 2015, 108, 377-386.	3.8	189
32	⁶⁸ Ga-labeled DOTA-Peptides and ⁶⁸ Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 314-321.	4.6	183
33	Changes in Bone Mineral Density, Body Composition, and Lipid Metabolism during Growth Hormone (GH) Treatment in Children with GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2423-2428.	3.6	180
34	Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy. <i>Gastroenterology</i> , 2010, 139, 742-753.e1.	1.3	177
35	[¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³]octreotate for somatostatin receptor-targeted radionuclide therapy. <i>International Journal of Cancer</i> , 2001, 92, 628-633.	5.1	176
36	IL-1 β and TGF β 2 synergistically induce endothelial to mesenchymal transition in an NF κ B-dependent manner. <i>Immunobiology</i> , 2013, 218, 443-454.	1.9	171

#	ARTICLE	IF	CITATIONS
37	Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues. <i>Accounts of Chemical Research</i> , 2009, 42, 873-880.	15.6	168
38	Identification of Thyroid Hormone Transporters. <i>Biochemical and Biophysical Research Communications</i> , 1999, 254, 497-501.	2.1	166
39	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with ^{111}In -Pentetreotide. <i>Neuroendocrinology</i> , 2009, 90, 184-189.	2.5	162
40	NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. <i>Pancreas</i> , 2010, 39, 784-798.	1.1	161
41	Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [^{177}Lu -DOTA 0 ,Tyr 3]Octreotate. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1361-1368.	5.0	161
42	Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA 0 ,d-Phe 1 ,Tyr 3]octreotide, a promising somatostatin analogue for radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 368-371.	2.1	159
43	Thyroid Hormone Transport by the Heterodimeric Human System L Amino Acid Transporter. <i>Endocrinology</i> , 2001, 142, 4339-4348.	2.8	158
44	Peptide-receptor radionuclide therapy for endocrine tumors. <i>Nature Reviews Endocrinology</i> , 2009, 5, 382-393.	9.6	152
45	Bone marrow dosimetry in peptide receptor radionuclide therapy with [^{177}Lu -DOTA 0 ,Tyr 3]octreotate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1138-1146.	6.4	151
46	Somatostatin analogue scintigraphy in carcinoid tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1993, 20, 283-92.	2.1	148
47	Endothelial progenitor cell-based neovascularization: implications for therapy. <i>Trends in Molecular Medicine</i> , 2009, 15, 180-189.	6.7	148
48	Peak bone mineral density, lean body mass and fractures. <i>Bone</i> , 2010, 46, 336-341.	2.9	140
49	Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2010, 40, 78-88.	4.6	140
50	Nephrotoxicity after PRRT with ^{177}Lu -DOTA-octreotate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1802-1811.	6.4	129
51	Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results. <i>Journal of Nuclear Medicine</i> , 2017, 58, 75-80.	5.0	129
52	Subacute haematotoxicity after PRRT with ^{177}Lu -DOTA-octreotate: prognostic factors, incidence and course. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 453-463.	6.4	125
53	Peptide receptor radionuclide therapy with ^{177}Lu -octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1219-1227.	6.4	121
54	Report on short-term side effects of treatments with ^{177}Lu -octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 743-748.	6.4	121

#	ARTICLE	IF	CITATIONS
55	Peptide receptor radionuclide therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2007, 21, 111-129.	4.7	120
56	Peptide Receptor Radionuclide Therapy With ¹⁷⁷ Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors. Pancreas, 2014, 43, 518-525.	1.1	120
57	Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nature Reviews Endocrinology, 2014, 10, 102-114.	9.6	120
58	Thyroxine and 3,5-Triiodothyronine Are Glucuronidated in Rat Liver by Different Uridine Diphosphate-Glucuronyltransferases*. Endocrinology, 1991, 128, 741-746.	2.8	117
59	Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 83S-91S.	5.0	117
60	Ontogeny of Iodothyronine Deiodinases in Human Liver1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2868-2874.	3.6	115
61	Radiolabelled peptides for tumour therapy: current status and future directions. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 463-469.	6.4	114
62	Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Medical and Pediatric Oncology, 2000, 35, 415-420.	1.0	113
63	Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1018-1031.	6.4	113
64	Deiodination of Thyroid Hormone by Human Liver. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 17-24.	3.6	112
65	Salvage Therapy with ¹⁷⁷ Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine, 2010, 51, 383-390.	5.0	112
66	Somatostatin receptor scintigraphy: Its value in tumor localization in patients with cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. American Journal of Medicine, 1994, 96, 305-312.	1.5	110
67	Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. , 1998, 75, 406-411.		109
68	Endothelial progenitor cells give rise to pro-angiogenic smooth muscle-like progeny. Cardiovascular Research, 2010, 86, 506-515.	3.8	109
69	Effects of therapy with [¹⁷⁷ Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. Journal of Nuclear Medicine, 2006, 47, 1599-606.	5.0	109
70	Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 99S-106S.	5.0	107
71	Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematology/Oncology Clinics of North America, 2016, 30, 179-191.	2.2	106
72	Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1136-1143.	6.4	105

#	ARTICLE	IF	CITATIONS
73	Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³]octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 749-755.	6.4	104
74	Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocrine-Related Cancer, 2011, 18, S27-S51.	3.1	104
75	Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 62S-6S.	5.0	103
76	“To Serve and Protect”: Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting. Journal of Nuclear Medicine, 2014, 55, 121-127.	5.0	101
77	PRRT genomic signature in blood for prediction of ¹⁷⁷ Lu-octreotate efficacy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1155-1169.	6.4	101
78	Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³]Octreotate. Journal of Nuclear Medicine, 2015, 56, 1647-1653.	5.0	97
79	Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. Seminars in Nuclear Medicine, 2016, 46, 225-238.	4.6	97
80	Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy. Seminars in Nuclear Medicine, 2010, 40, 209-218.	4.6	95
81	Plasma Membrane Transport of Thyroid Hormones and Its Role in Thyroid Hormone Metabolism and Bioavailability. , 2001, 22, 451-476.		92
82	Combination radionuclide therapy using ¹⁷⁷ Lu- and ⁹⁰ Y-labeled somatostatin analogs. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 13S-7S.	5.0	92
83	Decreased transport of thyroxine (T ₄), 3,5-triiodothyronine (T ₃) and 3,5-triiodothyronine (rT ₃) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs. FEBS Letters, 1982, 140, 229-233.	2.8	90
84	Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸ Ga]SB3 and PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 964-973.	6.4	90
85	Characteristics of SnO ₂ -based ⁶⁸ Ge/ ⁶⁸ Ga generator and aspects of radiolabelling DOTA-peptides. Applied Radiation and Isotopes, 2011, 69, 308-315.	1.5	88
86	Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine, 2018, 59, 452-458.	5.0	88
87	Tumour uptake of the radiolabelled somatostatin analogue [DOTA ⁰ ,TYR ³]octreotide is dependent on the peptide amount. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 693-698.	6.4	81
88	Peptide Receptor Radionuclide Therapy. Annals of the New York Academy of Sciences, 2004, 1014, 234-245.	3.8	80
89	Somatostatin receptor imaging in patients with sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1284-1292.	6.4	79
90	Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: ⁸⁶ Y or ⁹⁰ Y imaging?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 57-68.	6.4	79

#	ARTICLE	IF	CITATIONS
91	FGF-2 inhibits Endothelial-Mesenchymal Transition through microRNA-20a-mediated repression of canonical TGF- β 2 Signaling. <i>Journal of Cell Science</i> , 2016, 129, 569-79.	2.0	77
92	Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1265-1272.	6.4	76
93	The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0. <i>Journal of Nuclear Medicine Technology</i> , 2011, 39, 317-324.	0.8	74
94	Bone Mineral Density and Body Composition before and during Treatment with Gonadotropin-Releasing Hormone Agonist in Children with Central Precocious and Early Puberty1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 370-373.	3.6	73
95	SPECT Study of Folate Receptor-Positive Malignant and Normal Tissues in Mice Using a Novel ^{99m} Tc-Radiofolate. <i>Journal of Nuclear Medicine</i> , 2008, 49, 310-317.	5.0	73
96	PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 895-906.	6.4	73
97	Site-Specific Intracoronary Heparin Delivery in Humans After Balloon Angioplasty. <i>Circulation</i> , 1997, 96, 154-165.	1.6	73
98	Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1312-1317.	2.1	72
99	Peptide receptor radionuclide therapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2005, 19, 595-616.	2.4	72
100	Vascular smooth muscle cells for use in vascular tissue engineering obtained by endothelial-to-mesenchymal transdifferentiation (EnMT) on collagen matrices. <i>Biomaterials</i> , 2008, 29, 3703-3711.	11.4	70
101	Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, F1314-F1322.	2.7	70
102	Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. , 1999, 81, 658-665.		69
103	Pre-clinical evaluation of [¹¹¹ In-DTPA-Pro1, Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphy. , 1999, 83, 657-663.		69
104	Somatostatin receptor imaging for neuroendocrine tumors. <i>Pituitary</i> , 2006, 9, 243-248.	2.9	69
105	A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1386-1396.	6.4	67
106	Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine. <i>Journal of Nuclear Medicine</i> , 2017, 58, 3S-9S.	5.0	66
107	Evaluation in vitro and in rats of ¹⁶¹ Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 608-616.	2.1	65
108	CARRIER-MEDIATED TRANSPORT OF THYROID HORMONE INTO RAT HEPATOCYTES IS RATE-LIMITING IN TOTAL CELLULAR UPTAKE AND METABOLISM. <i>Endocrinology</i> , 1986, 119, 1870-1872.	2.8	63

#	ARTICLE	IF	CITATIONS
109	Epigenetic Regulation of Endothelial-to-Mesenchymal Transition in Chronic Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1986-1996.	2.4	63
110	Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1650-6.	5.0	63
111	The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 312-315.	6.4	62
112	The decrease in histone methyltransferase EZH2 in response to fluid shear stress alters endothelial gene expression and promotes quiescence. <i>Angiogenesis</i> , 2016, 19, 9-24.	7.2	62
113	Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA 0, d -Phe 1, Tyr 3]octreotide, a promising somatostatin analogue for radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 368-371.	6.4	62
114	Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 92S-8S.	5.0	60
115	Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011, 40, 173-185.	3.2	59
116	Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences. <i>Nuclear Medicine and Biology</i> , 2007, 34, 633-641.	0.6	58
117	Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 867-881.	2.4	58
118	Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy. <i>Neuroendocrinology</i> , 2013, 97, 74-85.	2.5	58
119	Imaging of activated macrophages in experimental osteoarthritis using folate-targeted animal single-photon-emission computed tomography/computed tomography. <i>Arthritis and Rheumatism</i> , 2011, 63, 1898-1907.	6.7	57
120	Adipose stromal cells primed with hypoxia and inflammation enhance cardiomyocyte proliferation rate in vitro through STAT3 and Erk1/2. <i>Journal of Translational Medicine</i> , 2013, 11, 39.	4.4	57
121	Candidates for peptide receptor radiotherapy today and in the future. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 67S-75S.	5.0	57
122	Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22 α expression in endothelial cells in response to interleukin-1 β and transforming growth factor- β 2. <i>Cellular Signalling</i> , 2015, 27, 1589-1596.	3.6	56
123	Non-coding RNA in endothelial-to-mesenchymal transition. <i>Cardiovascular Research</i> , 2019, 115, 1716-1731.	3.8	56
124	Endothelial Plasticity: Shifting Phenotypes through Force Feedback. <i>Stem Cells International</i> , 2016, 2016, 1-15.	2.5	55
125	Somatostatin Receptor Scintigraphy in Patients with Carcinoid Tumors. <i>World Journal of Surgery</i> , 1996, 20, 157-161.	1.6	54
126	Octreoscan Radioreceptor Imaging. <i>Endocrine</i> , 2003, 20, 307-312.	2.2	54

#	ARTICLE	IF	CITATIONS
127	Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. <i>European Journal of Pharmacology</i> , 1994, 271, 371-378.	3.5	52
128	Pemetrexed Improves Tumor Selectivity of ¹¹¹ In-DTPA-Folate in Mice with Folate Receptor-Positive Ovarian Cancer. <i>Journal of Nuclear Medicine</i> , 2008, 49, 623-629.	5.0	52
129	Crucial role for somatostatin receptor subtype 2 in determining the uptake of [¹¹¹ In-DTPA-D-Phe ¹]octreotide in somatostatin receptor-positive organs. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1315-21.	5.0	51
130	Long-Term Effects of Growth Hormone Therapy on Bone Mineral Density, Body Composition, and Serum Lipid Levels in Growth Hormone Deficient Children: A 6-Year Follow-Up Study. <i>Hormone Research in Paediatrics</i> , 2002, 58, 207-214.	1.8	50
131	Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2275-2281.	0.7	50
132	Glomerular Endothelial Cells as Instigators of Glomerular Sclerotic Diseases. <i>Frontiers in Pharmacology</i> , 2020, 11, 573557.	3.5	50
133	Sensitivity of ¹²³ I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 768-774.	6.4	49
134	Inhomogeneous localization of radioactivity in the human kidney after injection of [(¹¹¹ In-DTPA)]octreotide. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1168-71.	5.0	49
135	A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (⁹⁰ Y), (¹¹¹ In), or (¹⁷⁷ Lu). <i>Journal of Nuclear Medicine</i> , 2004, 45, 1260-9.	5.0	49
136	Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. <i>Journal of the American College of Cardiology</i> , 1996, 28, 447-454.	2.8	48
137	The Use of Somatostatin Receptor Scintigraphy in the Differential Diagnosis of Pancreatic Duct Cancers and Islet Cell Tumors. <i>Annals of Surgery</i> , 1996, 224, 119-124.	4.2	48
138	Thyroid Hormone Transport by the Heterodimeric Human System L Amino Acid Transporter. <i>Endocrinology</i> , 2001, 142, 4339-4348.	2.8	48
139	Octreotide and Related Somatostatin Analogs in the Diagnosis and Treatment of Pituitary Disease and Somatostatin Receptor Scintigraphy. <i>Frontiers in Neuroendocrinology</i> , 1993, 14, 27-55.	5.2	47
140	No difference between prednisolone and dexamethasone treatment in bone mineral density and growth in long term survivors of childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2006, 46, 88-93.	1.5	47
141	Long-term prognostic value of dobutamine stress echocardiography compared with myocardial perfusion scanning in patients unable to perform exercise tests. <i>American Journal of Medicine</i> , 2004, 117, 1-9.	1.5	45
142	Long-term toxicity of [¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³]octreotate in rats. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 219-227.	6.4	45
143	Somatostatin analogs for the treatment of neuroendocrine tumors. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 9-17.	5.9	45
144	Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³]octreotate. <i>Endocrine-Related Cancer</i> , 2017, 24, 243-251.	3.1	45

#	ARTICLE	IF	CITATIONS
145	Internalization of [DOTA ⁰ ,125I-Tyr ³]Octreotide by Somatostatin Receptor-Positive Cells In Vitro and In Vivo: Implications for Somatostatin Receptor-Targeted Radio-guided Surgery. Proceedings of the Association of American Physicians, 1999, 111, 63-69.	2.0	44
146	Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA ⁰ ,Tyr ³]octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 763-771.	6.4	43
147	Comparison of dobutamine stress echocardiography and technetium-99m sestamibi single-photon emission tomography for the diagnosis of coronary artery disease in hypertensive patients with and without left ventricular hypertrophy. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 25, 69-78.	6.4	42
148	99mTc-MIBI, 99mTc-Tetrofosmin and 99mTc-Q12 In Vitro and In Vivo. Nuclear Medicine and Biology, 1998, 25, 233-240.	0.6	42
149	Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends in Endocrinology and Metabolism, 2006, 17, 19-25.	7.1	42
150	CD34 ⁺ cells augment endothelial cell differentiation of CD14 ⁺ endothelial progenitor cells <i>in vitro</i> . Journal of Cellular and Molecular Medicine, 2009, 13, 2521-2533.	3.6	42
151	A global downregulation of microRNAs occurs in human quiescent satellite cells during myogenesis. Differentiation, 2012, 84, 314-321.	1.9	42
152	Peptide receptor radionuclide therapy in vitro using [111In-DTPA ⁰]octreotide. Journal of Nuclear Medicine, 2003, 44, 98-104.	5.0	42
153	Different Regulation of Thyroid Hormone Transport in Liver and Pituitary: Its Possible Role in the Maintenance of Low T3 Production during Nonthyroidal Illness and Fasting in Man. Thyroid, 1996, 6, 359-368.	4.5	41
154	Efficient differentiation of CD14 ⁺ monocytic cells into endothelial cells on degradable biomaterials. Biomaterials, 2007, 28, 1470-1479.	11.4	41
155	Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³]Octreotate. Journal of Nuclear Medicine, 2013, 54, 1689-1696.	5.0	41
156	Calcioprotein Particles. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1607-1624.	2.4	40
157	Comparison of uptake of 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-012 into human breast cancer cell lines. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1361-1366.	2.1	39
158	Accuracy of dobutamine tetrofosmin myocardial perfusion imaging for the noninvasive diagnosis of transplant coronary artery stenosis. Journal of Heart and Lung Transplantation, 2000, 19, 360-366.	0.6	39
159	The flow dependency of Tie2 expression in endotoxemia. Intensive Care Medicine, 2013, 39, 1262-1271.	8.2	39
160	mTOR Inhibitor RAD001 Promotes Metastasis in a Rat Model of Pancreatic Neuroendocrine Cancer. Cancer Research, 2013, 73, 12-18.	0.9	39
161	Nitric Oxide-cGMP Signaling in Hypertension. Hypertension, 2020, 76, 1055-1068.	2.7	39
162	Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1854-1860.	6.4	38

#	ARTICLE	IF	CITATIONS
163	Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1758-1766.	6.4	38
164	Somatostatin Analogs in the Treatment of Acromegaly. <i>Endocrinology and Metabolism Clinics of North America</i> , 1992, 21, 737-752.	3.2	37
165	Echocardiographic and Radionuclide Pulmonary Blood Flow Patterns After Transcatheter Closure of Patent Ductus Arteriosus. <i>Circulation</i> , 1996, 94, 126-129.	1.6	37
166	Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. <i>International Journal of Cancer</i> , 1999, 81, 767-771.	5.1	36
167	Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1968-1976.	6.4	36
168	Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. <i>Journal of Nuclear Medicine</i> , 2007, 48, 88-93.	5.0	36
169	Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction. <i>American Heart Journal</i> , 1996, 131, 1088-1096.	2.7	35
170	Expression of Rat Liver Cell Membrane Transporters for Thyroid Hormone in <i>Xenopus laevis</i> Oocytes1. <i>Endocrinology</i> , 1997, 138, 1841-1846.	2.8	34
171	Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model. <i>International Journal of Cancer</i> , 2003, 104, 376-379.	5.1	34
172	Human adipose tissue-derived stromal cells act as functional pericytes in mice and suppress high-glucose-induced proinflammatory activation of bovine retinal endothelial cells. <i>Diabetologia</i> , 2018, 61, 2371-2385.	6.3	34
173	Validation of Somatostatin Receptor Scintigraphy in the Localization of Neuroendocrine Tumors. <i>Acta OncolÁgica</i> , 1993, 32, 167-170.	1.8	33
174	Transport of thyroxine into cultured hepatocytes: effects of mild nonáthyroidal illness and calorie restriction in obese subjects. <i>Clinical Endocrinology</i> , 1994, 40, 79-85.	2.4	33
175	Safety, Hemodynamic Profile, and Feasibility of Dobutamine Stress Technetium Myocardial Perfusion Single-Photon Emission CT Imaging for Evaluation of Coronary Artery Disease in the Elderly. <i>Chest</i> , 2000, 117, 649-656.	0.8	33
176	Evidence that the uptake of tri-iodo-l-thyronine by human erythrocytes is carrier-mediated but not energy-dependent. <i>Biochemical Journal</i> , 1982, 208, 27-34.	3.7	32
177	Preoperative comparison of different noninvasive strategies for predicting improvement in left ventricular function after coronary artery bypass grafting. <i>American Journal of Cardiology</i> , 2003, 92, 1-4.	1.6	31
178	The 6-chromanol derivate SUL-109 enables prolonged hypothermic storage of adipose tissue-derived stem cells. <i>Biomaterials</i> , 2017, 119, 43-52.	11.4	31
179	Endothelium-derived stromal cells contribute to hematopoietic bone marrow niche formation. <i>Cell Stem Cell</i> , 2021, 28, 653-670.e11.	11.1	31
180	2 The clinical use of somatostatin analogues in the treatment of cancer. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1990, 4, 29-49.	1.0	30

#	ARTICLE	IF	CITATIONS
181	Accuracy of exercise stress technetium 99m sestamibi SPECT imaging in the evaluation of the extent and location of coronary artery disease in patients with an earlier myocardial infarction. <i>Journal of Nuclear Cardiology</i> , 2000, 7, 432-438.	2.1	30
182	Dynamic and Static Small-Animal SPECT in Rats for Monitoring Renal Function After ¹⁷⁷ Lu-Labeled Tyr ³ -Octreotate Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1962-1968.	5.0	30
183	Activation of Retinal Angiogenesis in Hyperglycemic <i>Zebrafish</i> Mutants. <i>Diabetes</i> , 2020, 69, 1020-1031.	0.6	30
184	Nephrotoxicity in Mice After Repeated Imaging Using ¹¹¹ In-Labeled Peptides. <i>Journal of Nuclear Medicine</i> , 2010, 51, 973-977.	5.0	29
185	Bone Mineral Density, Growth, and Thyroid Function in Long-Term Survivors of Pediatric Hodgkin's Lymphoma Treated with Chemotherapy Only. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1904-1909.	3.6	28
186	Gastrin Releasing Peptide Receptor-Directed Radioligands Based on a Bombesin Antagonist: Synthesis, ¹¹¹ In-Labeling, and Preclinical Profile. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2374-2384.	6.4	28
187	The (R)-enantiomer of the 6-chromanol derivate SUL-121 improves renal graft perfusion via antagonism of the α_1 -adrenoceptor. <i>Scientific Reports</i> , 2019, 9, 13.	3.3	28
188	Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin. <i>Bioconjugate Chemistry</i> , 2018, 29, 1774-1784.	3.6	27
189	[^{99m} Tc]Demotate 2 in the detection of sst2-positive tumours: a preclinical comparison with [¹¹¹ In]DOTA-tate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 831-840.	6.4	26
190	Bone Mineral Density and Body Composition in Adolescents with Childhood-Onset Growth Hormone Deficiency. <i>Hormone Research in Paediatrics</i> , 2009, 71, 364-371.	1.8	26
191	The Effect of Donor Variation and Senescence on Endothelial Differentiation of Human Mesenchymal Stromal Cells. <i>Tissue Engineering - Part A</i> , 2013, 19, 2318-2329.	3.1	26
192	Micromanaging cardiac regeneration: Targeted delivery of microRNAs for cardiac repair and regeneration. <i>World Journal of Cardiology</i> , 2016, 8, 163.	1.5	26
193	From Outside to Inside? Dose-Dependent Renal Tubular Damage After High-Dose Peptide Receptor Radionuclide Therapy in Rats Measured with <i>In Vivo</i> ^{99m} Tc-DMSA-SPECT and Molecular Imaging. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 40-49.	1.0	25
194	Treatment of Patients Who Have Endocrine Gastroenteropancreatic Tumors with Radiolabeled Somatostatin Analogues. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 561-573.	2.2	25
195	Recurrent incarceration of the retroverted gravid uterus at term - two times transvaginal caesarean section: a case report. <i>Journal of Medical Case Reports</i> , 2009, 3, 103.	0.8	25
196	The relation between 25-hydroxyvitamin D with peak bone mineral density and body composition in healthy young adults. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2011, 24, 355-60.	0.9	25
197	Uptake of [¹¹¹ In-DTPA]octreotide in the rat kidney is inhibited by colchicine and not by fructose. <i>Journal of Nuclear Medicine</i> , 2004, 45, 709-13.	5.0	25
198	[¹¹¹ In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. <i>EJNMMI Research</i> , 2012, 2, 25.	2.5	24

#	ARTICLE	IF	CITATIONS
199	Improving the <i>In Vivo</i> Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2016, 31, 20-28.	1.0	24
200	Longitudinal Follow-Up of Bone Density and Body Composition in Children with Precocious or Early Puberty before, during and after Cessation of GnRH Agonist Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 506-512.	3.6	24
201	Prognostic Implications of a Normal Stress Technetium-99m Tetrofosmin Myocardial Perfusion Study in Patients With a Healed Myocardial Infarct and/or Previous Coronary Revascularization. <i>American Journal of Cardiology</i> , 2006, 97, 1-6.	1.6	23
202	Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. <i>International Journal of Cancer</i> , 2010, 126, 2826-2834.	5.1	23
203	[¹¹¹ In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-Arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 179-187.	1.0	23
204	Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [¹¹¹ In-DOTA]MG11—first estimates for clinical translation. <i>EJNMMI Research</i> , 2016, 6, 15.	2.5	23
205	Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 775-781.	2.1	22
206	Dobutamine stress echocardiography and technetium-99m-tetrofosmin/fluorine 18-fluorodeoxyglucose single-photon emission computed tomography and influence of resting ejection fraction to assess myocardial viability in patients with severe left ventricular dysfunction and healed myocardial infarction. <i>American Journal of Cardiology</i> , 1999, 84, 130-134.	1.6	22
207	99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 193-196.	6.4	22
208	Tyr3-Octreotide and Tyr3-Octreotate Radiolabeled with ¹⁷⁷ Lu or ⁹⁰ Y: Peptide Receptor Radionuclide Therapy Results In Vitro. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 761-768.	1.0	22
209	Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys. <i>Nuclear Medicine and Biology</i> , 2007, 34, 603-608.	0.6	22
210	MicroRNA-374b induces endothelial-to-mesenchymal transition and early lesion formation through the inhibition of MAPK7 signaling. <i>Journal of Pathology</i> , 2019, 247, 456-470.	4.5	22
211	^{99m} Tc Radiotracers Based on Human GRP(18-27): Synthesis and Comparative Evaluation. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1797-1803.	5.0	21
212	Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?. <i>European Journal of Endocrinology</i> , 2006, 155, 717-723.	3.7	20
213	Tumor Response Assessment to Treatment with [¹⁷⁷ Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1359-1366.	5.0	20
214	Generating New Blood Flow: Integrating Developmental Biology and Tissue Engineering. <i>Trends in Cardiovascular Medicine</i> , 2008, 18, 312-323.	4.9	19
215	Therapy using labelled somatostatin analogues: comparison of the absorbed doses with ¹¹¹ In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. <i>Nuclear Medicine Communications</i> , 2008, 29, 283-290.	1.1	19
216	microRNA Expression Profile in the Vitreous of Proliferative Diabetic Retinopathy Patients and Differences from Patients Treated with Anti-VEGF Therapy. <i>Translational Vision Science and Technology</i> , 2020, 9, 16.	2.2	19

#	ARTICLE	IF	CITATIONS
217	Human Milk Oligosaccharides Mediate the Crosstalk Between Intestinal Epithelial Caco-2 Cells and Lactobacillus Plantarum WCFS1 in an In Vitro Model with Intestinal Peristaltic Shear Force. <i>Journal of Nutrition</i> , 2020, 150, 2077-2088.	2.9	19
218	Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1716-20.	5.0	19
219	Anticancer activity of targeted proapoptotic peptides. <i>Journal of Nuclear Medicine</i> , 2006, 47, 122-9.	5.0	19
220	Clinical applications of somatostatin analogs. <i>Trends in Endocrinology and Metabolism</i> , 1990, 1, 139-144.	7.1	18
221	Somatostatin receptor scintigraphy using [¹¹¹ In-DTPA 0]RC-160 in humans: a comparison with [¹¹¹ In-DTPA 0]octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 182-186.	6.4	18
222	Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [⁹⁰ Y-DOTA ⁰ ,Tyr ³]octreotide solutions containing free ⁹⁰ Y ³⁺ . <i>Nuclear Medicine and Biology</i> , 2004, 31, 821-824.	0.6	18
223	Reduction of Renal Uptake of Radiolabeled Octreotate by Amifostine Coadministration. <i>Journal of Nuclear Medicine</i> , 2012, 53, 749-753.	5.0	18
224	[¹¹¹ In-DOTA]LTT-SS28, a First Pansomatostatin Radioligand for in Vivo Targeting of Somatostatin Receptor-Positive Tumors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6564-6571.	6.4	18
225	Graft regeneration and host liver atrophy after auxiliary heterotopic liver transplantation for chronic liver failure. <i>Hepatology</i> , 1992, 15, 54-57.	7.3	17
226	Efficacy of percutaneous intramyocardial injections using a nonfluoroscopic 3-D mapping based catheter system. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 527-533.	2.6	17
227	Pleiotropism of Adiponectin. <i>Circulation Research</i> , 2009, 104, 1029-1031.	4.5	17
228	Optimization of the culturing conditions of human umbilical cord blood-derived endothelial colony-forming cells under xeno-free conditions applying a transcriptomic approach. <i>Genes To Cells</i> , 2010, 15, 671-687.	1.2	17
229	Liver and Vertebral Uptake of Tc-99m Macroaggregated Albumin (MAA). <i>Clinical Nuclear Medicine</i> , 2004, 29, 793-794.	1.3	16
230	The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1. <i>Journal of Personalized Medicine</i> , 2021, 11, 103.	2.5	16
231	Molecular Imaging and Treatment of Malignant Gliomas Following Adenoviral Transfer of the Herpes Simplex Virus-Thymidine Kinase Gene and the Somatostatin Receptor Subtype 2 Gene. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 111-120.	1.0	15
232	Diagnostic imaging of dopamine receptors in pituitary adenomas. <i>European Journal of Endocrinology</i> , 2007, 156, S53-S56.	3.7	15
233	Heparin coating of poly(ethylene terephthalate) decreases hydrophobicity, monocyte/leukocyte interaction and tissue interaction. <i>Colloids and Surfaces B: Biointerfaces</i> , 2008, 67, 46-53.	5.0	15
234	In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin ¹¹¹ In-radioligands. <i>Nuclear Medicine and Biology</i> , 2015, 42, 824-832.	0.6	15

#	ARTICLE	IF	CITATIONS
235	99mTc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice. <i>Nuclear Medicine and Biology</i> , 2016, 43, 347-354.	0.6	15
236	The 6-hydroxychromanol derivative SUL-109 ameliorates renal injury after deep hypothermia and rewarming in rats. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2128-2138.	0.7	15
237	Endocrine aspects of the diagnosis and treatment of primary brain tumours. <i>Clinical Endocrinology</i> , 1992, 37, 1-10.	2.4	14
238	Diagnostic Versus Therapeutic Doses of [177Lu-DOTA-Tyr3]-Octreotate: Uptake and Dosimetry in Somatostatin Receptor-Positive Tumors and Normal Organs. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 151-159.	1.0	14
239	Expression of Rat Liver Cell Membrane Transporters for Thyroid Hormone in <i>Xenopus laevis</i> Oocytes. <i>Endocrinology</i> , 1997, 138, 1841-1846.	2.8	14
240	Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 107S-14S.	5.0	14
241	Rapid Sulfation of 3,5-Triiodothyronine in Native <i>Xenopus laevis</i> Oocytes. <i>Endocrinology</i> , 1998, 139, 596-600.	2.8	13
242	Tumor Diagnosis with New ¹¹¹ In-Radioligands Based on Truncated Human Gastrin Releasing Peptide Sequences: Synthesis and Preclinical Comparison. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8579-8587.	6.4	13
243	The microRNA-7-mediated reduction in EPAC-1 contributes to vascular endothelial permeability and eNOS uncoupling in murine experimental retinopathy. <i>Acta Diabetologica</i> , 2017, 54, 581-591.	2.5	13
244	Perfusion and Contractile Reserve in Chronic Dysfunctional Myocardium: Relation to Functional Outcome After Surgical Revascularization. <i>Circulation</i> , 2002, 106, .	1.6	13
245	Combined measurements of plasma aromatic l-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 1045-1052.	0.7	12
246	Interaction between Epac1 and miRNA-7 in airway smooth muscle cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 795-797.	3.0	12
247	[DOTA]Somatostatin-14 analogs and their ¹¹¹ In-radioligands: Effects of decreasing ring-size on sst1 ⁵ profile, stability and tumor targeting. <i>European Journal of Medicinal Chemistry</i> , 2014, 73, 30-37.	5.5	12
248	The novel compound Sul-121 inhibits airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease. <i>Scientific Reports</i> , 2016, 6, 26928.	3.3	12
249	Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1712-1718.	5.0	12
250	Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [¹¹¹ In-DTPA]octreotide. <i>Journal of Nuclear Medicine</i> , 2005, 46, 2057-60.	5.0	12
251	Minireview: Receptor Imaging of Human Diseases Using Radiolabeled Peptides. <i>Journal of Receptor and Signal Transduction Research</i> , 1995, 15, 379-392.	2.5	11
252	Relation between QT dispersion and myocardial viability in ischemic cardiomyopathy. <i>American Journal of Cardiology</i> , 2003, 92, 712-715.	1.6	11

#	ARTICLE	IF	CITATIONS
253	Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the ¹¹¹ In-SB3/ ¹¹¹ In-SB4 Radiotracer Pair. <i>Molecules</i> , 2019, 24, 1015.	3.8	11
254	Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 76S-82S.	5.0	11
255	The kinetics of thyroid hormone transporters and their role in non-thyroidal illness and starvation. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 323-338.	4.7	10
256	Cellular plasticity: the good, the bad, and the ugly? Microenvironmental influences on progenitor cell therapy. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012, 90, 275-285.	1.4	10
257	Comparative evaluation of the new GRPR-antagonist ¹¹¹ In-SB9 and ¹¹¹ In-AMBA in prostate cancer models: Implications of in vivo stability. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 646-655.	1.0	10
258	In Vivo and In Vitro Detection of Dopamine D2 Receptors in Uveal Melanomas. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 895-902.	1.0	9
259	<i>In Vivo</i> Enzyme Inhibition Improves the Targeting of [¹⁷⁷ Lu]DOTA-GRP(13-27) in GRPR-Positive Tumors in Mice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 359-367.	1.0	9
260	One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [^{99m} Tc]Tc-DB4 and [¹¹¹ In]In-SG4 in Mice Treated with Entresto. <i>Pharmaceutics</i> , 2020, 12, 1145.	4.5	9
261	Adaptive changes in transmembrane transport and metabolism of triiodothyronine in perfused livers of fed and fasted hypothyroid and hyperthyroid rats. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 1355-1361.	3.4	8
262	Combined implantation of CD34 + and CD14 + cells increases neovascularization through amplified paracrine signalling. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2013, 7, 118-128.	2.7	8
263	Localization of ^{99m} Tc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses. <i>Pharmaceutics</i> , 2019, 12, 42.	3.8	8
264	[^{99m} Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models. <i>Molecules</i> , 2020, 25, 3418.	3.8	8
265	Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands. <i>Pharmaceutics</i> , 2020, 12, 528.	4.5	8
266	Reduced T3 deiodination by the human hepatoblastoma cell line HepG2 caused by deficient T3 sulfation. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1993, 1157, 114-118.	2.4	7
267	Optimizing the Profile of [^{99m} Tc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7926.	4.1	7
268	SUL-151 Decreases Airway Neutrophilia as a Prophylactic and Therapeutic Treatment in Mice after Cigarette Smoke Exposure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4991.	4.1	7
269	Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimetabolic effects of hybrids of cytostatic drugs and peptides. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 191S-8S.	5.0	7
270	Inhibition of kidney uptake of radiolabeled somatostatin analogs: amino acids or gelofusine?. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1730-1; author reply 1731.	5.0	7

#	ARTICLE	IF	CITATIONS
271	Therapeutic use of radiolabelled peptides. <i>Annals of Oncology</i> , 2000, 11, 267-272.	1.2	6
272	Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr3]octreotate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1843-1852.	6.4	6
273	Klotho Deficiency Induces Arteriolar Hyalinosis in a Trade-Off with Vascular Calcification. <i>American Journal of Pathology</i> , 2019, 189, 2503-2515.	3.8	6
274	The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1681-7.	5.0	6
275	Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats. <i>Nuclear Medicine and Biology</i> , 1997, 24, 749-753.	0.6	5
276	Torpor enhances synaptic strength and restores memory performance in a mouse model of Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 15486.	3.3	5
277	Euro-Collins Solution Versus Ulw-Solution for Long-Term Liver Preservation in the Isolated Rat-Liver Perfusion Model. <i>HPB Surgery</i> , 1991, 4, 313-320.	2.2	5
278	Dobutamine stress thallium-201 single-photon emission tomography versus echocardiography for evaluation of the extent and location of coronary artery disease late after myocardial infarction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 467-473.	6.4	4
279	Five Stabilized 111In-Labeled Neurotensin Analogs in Nude Mice Bearing HT29 Tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 374-382.	1.0	4
280	Reciprocal regulation of endothelial-mesenchymal transition by MAPK7 and EZH2 in intimal hyperplasia and coronary artery disease. <i>Scientific Reports</i> , 2021, 11, 17764.	3.3	4
281	[177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy. <i>International Journal of Cancer</i> , 2001, 92, 628-633.	5.1	4
282	Peptides for Radionuclide Therapy. , 2008, , 117-144.		4
283	Towards prevention of ischemia-reperfusion kidney injury: Pre-clinical evaluation of 6-chromanol derivatives and the lead compound SUL-138. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 168, 106033.	4.0	4
284	Somatostatin Receptors in Gastroenteropancreatic Tumors. <i>Digestive Surgery</i> , 1996, 13, 161-169.	1.2	3
285	Site-specific intravascular administration of drugs: History of a method applicable in humans. , 1997, 41, 342-347.		3
286	Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method. <i>Anti-Cancer Drugs</i> , 2006, 17, 63-67.	1.4	3
287	Autologous Lipofilling Improves Clinical Outcome in Patients With Symptomatic Dermal Scars Through Induction of a Pro-Regenerative Immune Response. <i>Aesthetic Surgery Journal</i> , 2021, , .	1.6	3
288	Tc-99m Sestamibi Before and During Treatment in a Patient With Sarcoidosis and Persistent Hyperparathyroidism. <i>Clinical Nuclear Medicine</i> , 2000, 25, 351-353.	1.3	3

#	ARTICLE	IF	CITATIONS
289	Endothelial function after the exposition of magnesium degradation products. <i>Materials Science and Engineering C</i> , 2022, 134, 112693.	7.3	3
290	Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study. <i>Pharmaceutics</i> , 2022, 14, 666.	4.5	3
291	Diffuse Lung and Stomach Uptake of Tc-99m Oxidronate (HDP). <i>Clinical Nuclear Medicine</i> , 2003, 28, 845-846.	1.3	2
292	Reduction of ⁶⁸ Ge activity containing liquid waste from ⁶⁸ Ga PET chemistry in nuclear medicine and radiopharmacy by solidification. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2011, 288, 303-306.	1.5	2
293	miRetrieve—an R package and web application for miRNA text mining. <i>NAR Genomics and Bioinformatics</i> , 2021, 3, lqab117.	3.2	2
294	The Role of Somatostatin Receptor Scintigraphy in Gastroenteropancreatic Endocrine Tumors. <i>Digestive Surgery</i> , 1994, 11, 456-460.	1.2	1
295	Scintigraphy of Pancreatic Neuroendocrine Tumors and Carcinoids. <i>Growth Hormone</i> , 2000, , 235-249.	0.2	1
296	Peptides and Monoclonal Antibodies in Oncology: An Introduction. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 591-592.	1.0	1
297	Somatostatin Receptor Imaging. <i>Growth Hormone</i> , 2004, , 203-214.	0.2	1
298	Site-Specific Intracoronary Delivery of Octreotide in Humans: A Pharmacokinetic Study to Determine Dose-Efficacy in Restenosis Prevention. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 133-139.	1.9	1
299	Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 749-750.	6.4	1
300	MicroRNAs in Tissue Engineering and Regenerative Medicine. , 2015, , 1159-1200.		1
301	The Effects of 6-Chromanol SUL-138 during Hypothermic Machine Perfusion on Porcine Deceased Donor Kidneys. <i>Transplantology</i> , 2021, 2, 304-314.	0.6	1
302	Somatostatin Receptor Targeted-Radio-Ablation of Tumors. <i>Growth Hormone</i> , 2004, , 233-249.	0.2	1
303	Thoracic bilateral sympathectomy attenuates oxidative stress and prevents ventricular remodelling in experimental pulmonary hypertension. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 61, 1337-1345.	1.4	1
304	Neuroendocrine Tumors. , 0, , 564-668.		0
305	545 PEPTIDE RECEPTOR TARGETING IS SUPERIOR TO METABOLIC TARGETING FOR <i>IN VIVO</i> IMAGING OF HUMAN PROSTATE CANCER XENOGRAFTS. <i>Journal of Urology</i> , 2010, 183, .	0.4	0
306	761 Circulating Neuroendocrine Gene Transcripts Accurately Identify GEP-NETs, Are Decreased by Surgery and Predict Tumor Progression and Recurrence. <i>Gastroenterology</i> , 2016, 150, S154.	1.3	0

#	ARTICLE	IF	CITATIONS
307	Obituary of Professor T.J. Visser. European Thyroid Journal, 2018, 7, 163-164.	2.4	0
308	P1940Reciprocal regulation of Endothelial-Mesenchymal Transition by MAPK7 and EZH2 activity in Intimal Hyperplasia and Coronary Artery Disease. European Heart Journal, 2019, 40, .	2.2	0
309	Carrier-Mediated Transport of Thyroid Hormone (TH) into Rat Hepatocytes is Rate Limiting in Total Cellular Uptake and Metabolism. , 1986, , 553-556.		0
310	MicroRNAs linking oxidative stress and diabetes. , 2020, , 97-106.		0